research chemical comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-04-17. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
== History == Frank P. Cotter developed a "simple self sealing check valve, adapted to be connected in the pipe connections without requiring special fittings and which may be readily opened for inspection or repair" 1907 (U.S. patent 865,631). Nikola Tesla invented a deceptively simple one-way valve for fluids in 1916, called a Tesla valve. It was patented in 1920 (U.S. patent 1,329,559).
== Regulation == Insofar as both IAPP and insulin are produced by the pancreatic β-cells, impaired β-cell function (due to lipotoxicity and glucotoxicity) will affect both insulin and IAPP production and release. Insulin and IAPP are regulated by similar factors since they share a common regulatory promoter motif. The IAPP promoter is also activated by stimuli which do not affect insulin, such as tumor necrosis factor alpha and fatty acids. One of the defining features of Type 2 diabetes is insulin resistance. This is a condition wherein the body is unable to utilize insulin effectively, resulting in increased insulin production; since proinsulin and proIAPP are cosecreted, this results in an increase in the production of proIAPP as well. Although little is known about IAPP regulation, its connection to insulin indicates that regulatory mechanisms that affect insulin also affect IAPP. Thus blood glucose levels play an important role in regulation of proIAPP synthesis.
After the battle, there were other several clashes between militiamen and gang members. Throughout the 2010s there were several arrests and convictions against militiamen and drug traffickers involved in the massacres. The militias managed to conquer several territories under the control of the Comando Vermelho, although some of them later returned to the gang's control after being reconquered during clashes. In November 2010, another massacre occurred between the military police and the CV, resulting in the deaths of 41 people. On 1 February 2012, during a raid conducted by the Polícia Militar (PM), a "Caveirão" was destroyed by the Comando Vermelho in the favela of Jacarezinho, no injuries were reported. During the course of the massacre, the CV and the militias began recruiting child soldiers. On 19 November 2016, during an operation of the PM, a military police helicopter was shot down by Comando Vermelho in the favela of Cidade de Deus, in the crash four policemen died. On 9 February 2020, a prominent militia faction leader, Adriano Magalhães da Nóbrega, also known as "Capitão Adriano" or "Gordinho", was seriously injured in a police operation and later died in a hospital. On 15 October, in one of the deadliest operations against militias, the PM clash with a convoy of the militias killing 12 paramilitaries on Itaguaí, also a policeman was injured. In the Morro do Fubá favela, the residents were forced to pay a monthly fee of 50 brazilian reals as part of a protection racket.
=== Mass spectrometry === Mass spectrometry provides information about the structure and composition of the complexes. Spectra for metal polycarbonyls are often easily interpretable, because the dominant fragmentation process is the loss of carbonyl ligands (m/z = 28).
Sources: en.wikipedia.org
December 12, 2008: Russia Andrei Klepach, a deputy economics minister of Russia, states that Russia has entered the recession, with two quarters of contraction expected, meaning Russia will fall short of reaching the 6.8% growth forecast for 2008.
=== Pleurodesis === It is used in pleurodesis (fusion of the pleura because of incessant pleural effusions). For this purpose, povidone-iodine is equally effective and safe as talc, and may be preferred because of easy availability and low cost.
== History == In March 2007, Eatza Pizza was bought by International Franchise Associates. Following the purchase, the corporate headquarters was moved from Arizona to Westport, Connecticut. In July 2008, International Franchise Associates filed for Chapter 7 bankruptcy. At that time, only five Eatza Pizza locations were left.
== Films == 2020 : Réveillons-nous, co-directed with Solal Moisan 2021 : Génération, co-directed with Solal Moisan 2022 : Glacier, co-directed with Solal Moisan 2022 : Désobéir, co-directed with Solal Moisan 2023 : Pourquoi on se bat, co-directed with Solal Moisan 2024 : PFAS : comment les industriels nous empoisonnent with Solal Moisan
Copper(II) sulfate remains "the most effective algicidal treatment". A related traditional use is the Bordeaux mixture, used to control fungus on fruits. Hydrated lime, as a biocide, is allowed in the production of organic foods.
Sources: en.wikipedia.org
== Killing == Around 9 a.m. on November 20, 1932, Robert Karriem had escorted James J. Smith into a room with a makeshift altar in the home at 1429 DuBois Street. Robert Karriem was described as a large 44 year old negro who had moved from Tennessee to Detroit on July 3, 1929. Smith, 40, was described as a negro. In the audience were twelve adult witnesses and Karriem's wife and children. Smith was asked if he would sacrifice his life for Islam, and Smith nodded his assent. Karriem then stabbed Smith in the chest, and proceeded to bludgeon him to death with an axle rod. Smith's body was found on the altar, stabbed through the chest with an 8-inch knife. A "cheap magazine" was open to a story about "mysticism of the desert", with the underlined phrase "The believer must be stabbed through the heart".
== Endogenous toxins == Endogenous reactive metabolites, such as peroxides, reactive oxygen species and reactive aldehydes, arise continuously from normal cellular metabolism and can damage proteins, lipids and nucleic acids if not controlled. Their detoxification involves both broad-spectrum and specialized enzymatic systems, including families that act on reactive carbonyls and other electrophiles, as well as dedicated pathways for particularly toxic intermediates. The glyoxalase system, consisting of glyoxalase I and II, uses glutathione to convert the reactive dicarbonyl methylglyoxal, a by-product of glycolysis, into D‑lactate. Antioxidant defence systems, including superoxide dismutases, catalase, peroxiredoxins and glutathione peroxidases, convert reactive oxygen species such as superoxide and hydrogen peroxide into less reactive products, and low-molecular-mass antioxidants such as glutathione, ascorbate and tocopherols further limit oxidative chain reactions. Together, these mechanisms maintain redox homeostasis and restrict the toxic effects of endogenous reactive metabolites.
=== Other drugs === Various other types of drugs have also been found to produce hypnotic-type effects in scientific research. Examples include histamine H3 receptor agonists like α-methylhistamine, BP 2.94, GT-2203 (VUF-5296), and SCH-50971, adenosine A1 and A2A receptor agonists like adenosine and YZG-331, and dopamine D1 receptor receptor antagonists like NNC 01-0687 (ADX-10061, CEE-03-310, NNC-687). Pellotine, a tetrahydroisoquinoline alkaloid found in Lophophora cacti species such as Lophophora diffusa (false peyote) and Lophophora williamsii (peyote), is a hypnotic that was previously marketed in Europe in the 1890s but was abandoned once cheaper barbiturates were introduced the next decade. It has been identified as a selective and potent serotonin 5-HT6 receptor weak partial agonist, serotonin 5-HT7 receptor inverse agonist, and serotonin 5-HT1D receptor ligand, with one or more of these actions possibly involved in its sedative and hypnotic effects. Tributyrin, a triglyceride (fat) and precursor or prodrug of butyric acid (butyrate), a short-chain fatty acid and major product of beneficial gut bacteria, has been found to increase slow wave sleep (SWS) and deep sleep in rodents and humans.
Vasoactive intestinal peptide, also known as vasoactive intestinal polypeptide or VIP, is a peptide hormone that is vasoactive in the intestine. VIP is a peptide of 28 amino acid residues that belongs to a glucagon/secretin superfamily, the ligand of class II G protein–coupled receptors. VIP is produced in many tissues of vertebrates including the gut, pancreas, neocortex, and suprachiasmatic nuclei of the hypothalamus in the brain. VIP stimulates contractility in the heart, causes vasodilation, increases glycogenolysis, lowers arterial blood pressure and relaxes the smooth muscle of trachea, stomach and gallbladder. In humans, the vasoactive intestinal peptide is encoded by the VIP gene. VIP has a half-life (t½) in the blood of about two minutes.
== Epidemiology == Few studies have examined the prevalence of FECD on a large scale. First assessed in a clinical setting, Fuchs himself estimated the occurrence of dystrophia epithelialis corneae to be one in every 2000 patients; a rate that is likely reflective of those who progress to advanced disease. Cross-sectional studies suggest a relatively higher prevalence of disease in European countries relative to other areas of the world. Fuchs dystrophy rarely affects individuals under 50 years of age.
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.